Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.

about

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Update in the Therapy of Advanced Neuroendocrine Tumors.

P2860

Q38695102-FE6889CF-C8E2-4C35-A2C8-0EB4780F7BD3 Q47393972-3181878E-B975-4B3D-990C-D56493B121CA Q49970741-E06BAA23-A7E0-4998-873F-9D525A4A4547

P2860

Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.

Item

http://www.wikidata.org/entity/Q38752443

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Inhibition of mTOR's Catalytic ...... Neuroendocrine Tumor Disease.

@en

type

Item

label

Inhibition of mTOR's Catalytic ...... Neuroendocrine Tumor Disease.

@en

prefLabel

Inhibition of mTOR's Catalytic ...... Neuroendocrine Tumor Disease.

@en

P1476

Inhibition of mTOR's Catalytic ...... Neuroendocrine Tumor Disease.

@en

P2093

Florentine Lewens

http://www.w3.org/2001/XMLSchema#string

Friederike Christen

http://www.w3.org/2001/XMLSchema#string

Helma Freitag

http://www.w3.org/2001/XMLSchema#string

Irina Grass

http://www.w3.org/2001/XMLSchema#string

Patricia Grabowski

http://www.w3.org/2001/XMLSchema#string

Sara Iwaszkiewicz

http://www.w3.org/2001/XMLSchema#string

P2860

GSK-3β: A Bifunctional Role in Cell Death Pathways

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins

PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms

mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

TOR signaling in growth and metabolism

Negative regulation of the serine/threonine kinase B-Raf by Akt

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif

4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications

P304

90-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000448843

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Britta Siegmund

Franziska Briest

P577

2016-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27513674

http://www.w3.org/2001/XMLSchema#string

P932

5475233

http://www.w3.org/2001/XMLSchema#string

Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.

about

P2860

P2860

Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932